RFK Jr. proposes steps to curb SSRI prescriptions; J&J pushes IBD drug; French regulators fine Novo, Lilly over weight-loss ads
U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced a set of initiatives aimed at reducing the prescribing of selective serotonin reuptake inhibitors, the most widely used class of antidepressants, citing concerns about dependence and difficulty quitting.
Johnson & Johnson is reported to be advancing an investigational drug for inflammatory bowel disease, signaling continued investment in the gastro‑intestinal market.
French health authorities have fined pharmaceutical companies Novo Nordisk and Eli Lilly for alleged violations in weight‑loss drug advertising, underscoring regulatory scrutiny of promotional practices.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Pharmalittle: We’re reading about RFK Jr. targeting antidepressants, J&J pushing an IBD drug, and more”
read at STAT ↗
comments(0)
5-min edit window · permanent after that